Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
Lexaria Bioscience Corp (NASDAQ:LEXX) provides an update on the GLP-1 industry and its strategic positioning. The company is developing its DehydraTECH™ drug delivery platform for application in the GLP-1 space, aiming to position it as essential technology for pharmaceutical companies. The GLP-1 sector has seen significant M&A activity, with major pharmaceutical companies like Novo Nordisk and Eli Lilly making substantial investments. Recent deals include Novo's $285 million license agreement with Ascendis Pharma, a $600 million collaboration with NanoVation Therapeutics, and the $1.08 billion acquisition of Inversago Pharma. The sector is projected to generate between $100 billion to $471 billion in annual revenue.
Lexaria Bioscience Corp (NASDAQ:LEXX) fornisce un aggiornamento sul settore GLP-1 e sulla sua posizione strategica. L'azienda sta sviluppando la sua piattaforma di somministrazione farmaceutica DehydraTECH™ per applicazioni nel campo del GLP-1, con l'obiettivo di posizionarla come tecnologia essenziale per le aziende farmaceutiche. Il settore GLP-1 ha visto un'attività significativa di fusioni e acquisizioni, con grandi aziende farmaceutiche come Novo Nordisk ed Eli Lilly che hanno effettuato sostanziali investimenti. Gli ultimi accordi includono il contratto di licenza da 285 milioni di dollari di Novo con Ascendis Pharma, una collaborazione da 600 milioni di dollari con NanoVation Therapeutics e l'acquisizione da 1,08 miliardi di dollari di Inversago Pharma. Si prevede che il settore generi un fatturato annuale compreso tra 100 e 471 miliardi di dollari.
Lexaria Bioscience Corp (NASDAQ:LEXX) proporciona una actualización sobre la industria GLP-1 y su posicionamiento estratégico. La compañía está desarrollando su plataforma de entrega de medicamentos DehydraTECH™ para su aplicación en el espacio GLP-1, con el objetivo de posicionarla como tecnología esencial para las empresas farmacéuticas. El sector GLP-1 ha visto una actividad significativa de fusiones y adquisiciones, con grandes compañías farmacéuticas como Novo Nordisk y Eli Lilly realizando inversiones sustanciales. Los acuerdos recientes incluyen el contrato de licencia de 285 millones de dólares de Novo con Ascendis Pharma, una colaboración de 600 millones de dólares con NanoVation Therapeutics y la adquisición de 1,08 mil millones de dólares de Inversago Pharma. Se proyecta que el sector genere entre 100 mil millones y 471 mil millones de dólares en ingresos anuales.
렉사리아 바이오사이언스 주식회사(NASDAQ:LEXX)는 GLP-1 산업에 대한 업데이트와 전략적 포지셔닝에 대해 제공합니다. 회사는 GLP-1 분야에 적용하기 위해 DehydraTECH™ 약물 전달 플랫폼을 개발하고 있으며, 이를 제약회사들의 필수 기술로 자리매김하고자 합니다. GLP-1 분야는 노보 노르디스크(Novo Nordisk)와 일라이 릴리(Eli Lilly)와 같은 주요 제약 회사들이 상당한 투자를 진행하면서 M&A 활동이 활발해졌습니다. 최근 거래에는 노보의 애센디스 파마(Ascendis Pharma)와의 2억 8,500만 달러 라이센스 계약, 나노베이션 제약(NanoVation Therapeutics)과의 6억 달러 협업, 인버사고 파마(Inversago Pharma)의 10억 8,000만 달러 인수가 포함됩니다. 이 분야는 연간 수익이 1,000억 달러에서 4,710억 달러에 이를 것으로 예상됩니다.
Lexaria Bioscience Corp (NASDAQ:LEXX) fournit une mise à jour sur l'industrie GLP-1 et son positionnement stratégique. L'entreprise développe sa plateforme de délivrance de médicaments DehydraTECH™ pour une application dans l'espace GLP-1, visant à la positionner comme une technologie essentielle pour les entreprises pharmaceutiques. Le secteur GLP-1 a connu une activité significative de fusions et acquisitions, avec de grandes entreprises pharmaceutiques comme Novo Nordisk et Eli Lilly réalisant des investissements substantiels. Les accords récents incluent l'accord de licence de 285 millions de dollars de Novo avec Ascendis Pharma, une collaboration de 600 millions de dollars avec NanoVation Therapeutics et l'acquisition d'Inversago Pharma pour 1,08 milliard de dollars. Le secteur devrait générer un chiffre d'affaires annuel compris entre 100 milliards et 471 milliards de dollars.
Die Lexaria Bioscience Corp (NASDAQ:LEXX) gibt ein Update zur GLP-1-Branche und ihrer strategischen Positionierung. Das Unternehmen entwickelt seine DehydraTECH™ Arzneimittelabgabetechnologie für Anwendungen im GLP-1-Bereich, mit dem Ziel, diese als wesentliche Technologie für Pharmaunternehmen zu positionieren. Der GLP-1-Sektor hat eine bedeutende M&A-Aktivität erlebt, wobei große Pharmakonzerne wie Novo Nordisk und Eli Lilly beträchtliche Investitionen getätigt haben. Zu den jüngsten Geschäften gehören Novos Lizenzvereinbarung über 285 Millionen Dollar mit Ascendis Pharma, eine Zusammenarbeit über 600 Millionen Dollar mit NanoVation Therapeutics und die Übernahme von Inversago Pharma für 1,08 Milliarden Dollar. Es wird prognostiziert, dass der Sektor jährliche Einnahmen zwischen 100 Milliarden und 471 Milliarden Dollar generieren wird.
- DehydraTECH platform being positioned in high-growth GLP-1 market with potential for pharmaceutical partnerships
- Company targeting rapidly expanding market projected to reach $100-471 billion annually
- None.
Insights
The GLP-1 market is experiencing unprecedented growth and consolidation, with major pharmaceutical companies making strategic moves through acquisitions and partnerships. The sector's valuation projections of
- Novo Nordisk's dominance with
$8.3 billion in Ozempic sales (H1 2024) - Multiple billion-dollar deals including Novo's
$16.5 billion Catalent acquisition - Technology platform licensing deals ranging from
$285 million to$1 billion
For Lexaria, positioning DehydraTECH as a delivery platform in this rapidly expanding market represents a significant opportunity, particularly given the industry's focus on improving drug delivery systems and patient outcomes. The company's strategy aligns with the current trend of major pharmaceuticals seeking technology platforms to enhance their GLP-1 products.
DehydraTECH™ for GLP-1 being optimized for global pharmaceutical use
KELOWNA, BC / ACCESSWIRE / November 7, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms provides the following glucagon-like peptide-1 ("GLP-1") industry update.
It is no surprise that Novo Nordisk's ("Novo") blockbuster drug, semaglutide, which is sold under the brand names Ozempic®, Wegovy®, and Rybelsus®, is the bestselling diabetes and weight loss drug in the world today. Novo has, for one hundred years, been the world's leading diabetes drug and research company, after receiving the extraction and purification techniques from the Canadian doctor who discovered insulin in 1921. They owned six of the world's top-15 bestselling diabetes drugs, for combined sales in 2022 of US
Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a "must-have" technology for larger companies seeking to develop, defend or increase their cash flows from existing drugs as well as to be utilized in early stages of drug development for next-gen GLP-1 drugs due to hit the market in 2026, 2027, and beyond.
An 'arm's race' of sorts has begun amongst the world's pharmaceutical companies once it became apparent that the GLP-1 drugs responsible for life-changing outcomes in diabetes management were also responsible for impressive weight-loss benefits. Close behind Novo is Eli Lilly with its own drug, tirzepatide, which is branded as both Mounjaro® and Zepbound®. Because of its dual action properties, working on both GLP-1 receptors and also glucose-dependant insulinotropic polypeptide pathways ("GIP"), tirzepatide is even more effective at weight loss and is expected by some analysts to reach
Global pharmaceutical companies are competing against each other in the GLP-1 space utilizing three main strategies:
Developing or acquiring their own new GLP-1 and related molecules under traditional drug development techniques;
Developing or acquiring technologies and intellectual property ("IP") that improves the delivery pharmacokinetics of GLP-1 in attempts to increase drug absorption and decrease drug side effects; and,
Developing or acquiring related technologies and IP that can act as platforms for improved drug performance and patient outcomes.
On November 4, 2024, Ascendis Pharma announced it had granted an exclusive worldwide license to its technology platform to Novo for Novo products in metabolic disease - obesity and type 2 diabetes. In return, Ascendis will be eligible to receive total payments of US
On September 18, 2024, it was reported that Novo was agreeing to pay NanoVation Therapeutics up to
On September 16, 2024, Korro Bio announced a collaboration wherein it could receive up to
In September 2024, Eli Lilly began working with Haya Therapeutics by way of up to a
In August, 2024, Canadian-based Inversago Pharma announced its pending acquisition by Novo for up to
In February, 2024 Viking Therapeutics announced positive Phase II weight-loss results from its GLP-1/GIP drug and watched its company valuation sore from less than
In February, Novo paid
In December, 2023, Eli Lilly agreed to pay up to
The GLP-1 and related drug sector has generated tens of billions of dollars in corporate M&A and licensing activity even as it is on its way to becoming one of the largest drug sectors in history with estimates widely ranging from
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 46 patents granted and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202
SOURCE: Lexaria Bioscience Corp.
View the original press release on accesswire.com
FAQ
What is Lexaria's strategy in the GLP-1 market?
How big is the projected market size for GLP-1 drugs?
What recent major deals have occurred in the GLP-1 sector?
